{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:54:05Z","timestamp":1791500045950,"version":"4.3.4"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-77547-4","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T18:24:46Z","timestamp":1788891886000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CD73 disruption with tumor-specific CRISPR\/Cas9 nanoparticles reduces adenosine-mediated immunosuppression and amplifies response to chemotherapy"],"prefix":"10.1038","volume":"17","author":[{"given":"Xinhong","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujing","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengfei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2932-1062","authenticated-orcid":false,"given":"Meng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2307-1376","authenticated-orcid":false,"given":"Yan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3652-9515","authenticated-orcid":false,"given":"Andy","family":"Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"77547_CR1","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.molcel.2020.05.034","volume":"78","author":"JE Bader","year":"2020","unstructured":"Bader, J. E., Voss, K. & Rathmell, J. C. Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy. Mol. Cell 78, 1019\u20131033 (2020).","journal-title":"Mol. Cell"},{"key":"77547_CR2","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41577-021-00541-y","volume":"21","author":"K DePeaux","year":"2021","unstructured":"DePeaux, K. & Delgoffe, G. M. Metabolic barriers to cancer immunotherapy. Nat. Rev. Immunol. 21, 785\u2013797 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"77547_CR3","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41571-019-0203-7","volume":"16","author":"X Li","year":"2019","unstructured":"Li, X. et al. Navigating metabolic pathways to enhance antitumor immunity and immunotherapy. Nat. Rev. Clin. Oncol. 16, 425\u2013441 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"77547_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.imlet.2018.03.007","volume":"205","author":"E Ferretti","year":"2019","unstructured":"Ferretti, E., Horenstein, A., Canzonetta, C., Costa, F. & Morandi, F. Canonical and non-canonical adenosinergic pathways. Immunol. Lett. 205, 25\u201330 (2019).","journal-title":"Immunol. Lett."},{"key":"77547_CR5","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.ccell.2019.10.007","volume":"36","author":"D Boison","year":"2019","unstructured":"Boison, D. & Yegutkin, G. G. Adenosine metabolism: emerging concepts for cancer therapy. Cancer Cell 36, 582\u2013596 (2019).","journal-title":"Cancer Cell"},{"key":"77547_CR6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nrc.2017.86","volume":"17","author":"D Vijayan","year":"2017","unstructured":"Vijayan, D., Young, A., Teng, M. W. & Smyth, M. J. Targeting immunosuppressive adenosine in cancer. Nat. Rev. Cancer 17, 709\u2013724 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"77547_CR7","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41571-020-0382-2","volume":"17","author":"B Allard","year":"2020","unstructured":"Allard, B., Allard, D., Buisseret, L. & Stagg, J. The adenosine pathway in immuno-oncology. Nat. Rev. Clin. Oncol. 17, 611\u2013629 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"77547_CR8","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1016\/j.drudis.2017.06.005","volume":"22","author":"L Antonioli","year":"2017","unstructured":"Antonioli, L. et al. Switching off CD73: a way to boost the activity of conventional and targeted antineoplastic therapies. Drug Discov. Today 22, 1686\u20131696 (2017).","journal-title":"Drug Discov. Today"},{"key":"77547_CR9","doi-asserted-by":"publisher","first-page":"2410545","DOI":"10.1002\/advs.202410545","volume":"12","author":"P Liu","year":"2025","unstructured":"Liu, P. et al. Co-delivery of aPD-L1 and CD73 inhibitor using calcium phosphate nanoparticles for enhanced melanoma immunotherapy with reduced toxicity. Adv. Sci. 12, 2410545 (2025).","journal-title":"Adv. Sci."},{"key":"77547_CR10","doi-asserted-by":"publisher","first-page":"2100007","DOI":"10.1002\/adfm.202100007","volume":"31","author":"H Xiong","year":"2021","unstructured":"Xiong, H. et al. Inspired epigenetic modulation synergy with adenosine inhibition elicits pyroptosis and potentiates cancer immunotherapy. Adv. Funct. Mater. 31, 2100007 (2021).","journal-title":"Adv. Funct. Mater."},{"key":"77547_CR11","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.ccell.2018.03.025","volume":"33","author":"DJ Konieczkowski","year":"2018","unstructured":"Konieczkowski, D. J., Johannessen, C. M. & Garraway, L. A. A Convergence-based framework for cancer drug resistance. Cancer Cell 33, 801\u2013815 (2018).","journal-title":"Cancer Cell"},{"key":"77547_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1146\/annurev-pharmtox-010715-103111","volume":"56","author":"MM Gottesman","year":"2016","unstructured":"Gottesman, M. M., Lavi, O., Hall, M. D. & Gillet, J. P. Toward a better understanding of the complexity of cancer drug resistance. Annu. Rev. Pharmacol. Toxicol. 56, 85\u2013102 (2016).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"77547_CR13","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1073\/pnas.0908801107","volume":"107","author":"J Stagg","year":"2010","unstructured":"Stagg, J. et al. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc. Natl. Acad. Sci. USA 107, 1547\u20131552 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"77547_CR14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nature15818","volume":"526","author":"L Naldini","year":"2015","unstructured":"Naldini, L. Gene therapy returns to centre stage. Nature 526, 351\u2013360 (2015).","journal-title":"Nature"},{"key":"77547_CR15","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s10585-007-9081-y","volume":"24","author":"X Zhi","year":"2007","unstructured":"Zhi, X. et al. RNA interference of ecto-5\u2019-nucleotidase (CD73) inhibits human breast cancer cell growth and invasion. Clin. Exp. Metastasis 24, 439\u2013448 (2007).","journal-title":"Clin. Exp. Metastasis"},{"key":"77547_CR16","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.addr.2020.04.010","volume":"168","author":"X Song","year":"2021","unstructured":"Song, X. et al. Delivery of CRISPR\/Cas systems for cancer gene therapy and immunotherapy. Adv. Drug Deliv. Rev. 168, 158\u2013180 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"77547_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01738-6","volume":"22","author":"Z Liu","year":"2023","unstructured":"Liu, Z. et al. Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy. Mol. Cancer 22, 35 (2023).","journal-title":"Mol. Cancer"},{"key":"77547_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56407-7","volume":"16","author":"K Li","year":"2025","unstructured":"Li, K. et al. Cascaded immunotherapy with implantable dual-drug depots sequentially releasing STING agonists and apoptosis inducers. Nat. Commun. 16, 1629 (2025).","journal-title":"Nat. Commun."},{"key":"77547_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53906-x","volume":"15","author":"J Song","year":"2024","unstructured":"Song, J., Wang, H., Meng, X., Li, W. & Qi, J. A hypoxia-activated and microenvironment-remodeling nanoplatform for multifunctional imaging and potentiated immunotherapy of cancer. Nat. Commun. 15, 10395 (2024).","journal-title":"Nat. Commun."},{"key":"77547_CR20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nri2216","volume":"8","author":"L Zitvogel","year":"2008","unstructured":"Zitvogel, L., Apetoh, L., Ghiringhelli, F. & Kroemer, G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8, 59\u201373 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"77547_CR21","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","volume":"17","author":"L Galluzzi","year":"2020","unstructured":"Galluzzi, L., Humeau, J., Buqu\u00e9, A., Zitvogel, L. & Kroemer, G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat. Rev. Clin. Oncol. 17, 725\u2013741 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"77547_CR22","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","volume":"3","author":"LA Emens","year":"2015","unstructured":"Emens, L. A. & Middleton, G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol. Res. 3, 436\u2013443 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"77547_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24902-2","volume":"12","author":"J Qi","year":"2021","unstructured":"Qi, J. et al. Synergistic effect of tumor chemo-immunotherapy induced by leukocyte-hitchhiking thermal-sensitive micelles. Nat. Commun. 12, 4755 (2021).","journal-title":"Nat. Commun."},{"key":"77547_CR24","doi-asserted-by":"publisher","first-page":"2101222","DOI":"10.1002\/adhm.202101222","volume":"10","author":"P Yan","year":"2021","unstructured":"Yan, P. et al. A redox-responsive nanovaccine combined with a2a receptor antagonist for cancer immunotherapy. Adv. Healthcare Mater. 10, 2101222 (2021).","journal-title":"Adv. Healthcare Mater."},{"key":"77547_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.addr.2019.11.005","volume":"168","author":"C-F Xu","year":"2021","unstructured":"Xu, C.-F. et al. Rational designs of in vivo CRISPR-Cas delivery systems. Adv. Drug Deliv. Rev. 168, 3\u201329 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"77547_CR26","doi-asserted-by":"publisher","first-page":"eaav7199","DOI":"10.1126\/sciadv.aav7199","volume":"5","author":"Y Pan","year":"2019","unstructured":"Pan, Y. et al. Near-infrared upconversion\u2013activated CRISPR-Cas9 system: a remote-controlled gene editing platform. Sci. Adv. 5, eaav7199 (2019).","journal-title":"Sci. Adv."},{"key":"77547_CR27","doi-asserted-by":"publisher","first-page":"eabc9450","DOI":"10.1126\/sciadv.abc9450","volume":"6","author":"D Rosenblum","year":"2020","unstructured":"Rosenblum, D. et al. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. Sci. Adv. 6, eabc9450 (2020).","journal-title":"Sci. Adv."},{"key":"77547_CR28","doi-asserted-by":"publisher","first-page":"eadi3602","DOI":"10.1126\/sciadv.adi3602","volume":"9","author":"N Song","year":"2023","unstructured":"Song, N. et al. Cascade dynamic assembly\/disassembly of DNA nanoframework, enabling the controlled delivery of the CRISPR-Cas9 system. Sci. Adv. 9, eadi3602 (2023).","journal-title":"Sci. Adv."},{"key":"77547_CR29","doi-asserted-by":"publisher","first-page":"370ra180","DOI":"10.1126\/scitranslmed.aag2942","volume":"8","author":"D Mathios","year":"2016","unstructured":"Mathios, D. et al. Anti\u2013PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM. Sci. Transl. Med. 8, 370ra180\u2013370ra180 (2016).","journal-title":"Sci. Transl. Med."},{"key":"77547_CR30","doi-asserted-by":"publisher","first-page":"E1239","DOI":"10.1073\/pnas.1718197115","volume":"115","author":"D Samanta","year":"2018","unstructured":"Samanta, D. et al. Chemotherapy induces enrichment of CD47\u2009+\u2009\/CD73\u2009+\u2009\/PDL1+ immune evasive triple-negative breast cancer cells. Proc. Natl. Acad. Sci. USA 115, E1239\u2013E1248 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"77547_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19540-z","volume":"11","author":"H Wang","year":"2020","unstructured":"Wang, H. et al. Biomaterial-based scaffold for in situ chemo-immunotherapy to treat poorly immunogenic tumors. Nat. Commun. 11, 5696 (2020).","journal-title":"Nat. Commun."},{"key":"77547_CR32","doi-asserted-by":"publisher","first-page":"22900","DOI":"10.1021\/acsnano.5c01541","volume":"19","author":"D Yu","year":"2025","unstructured":"Yu, D. et al. NIR-II engineered exosome nanotheranostic probes for \u201coriented blasting\u201d in orthotopic glioblastoma. ACS Nano 19, 22900\u201322913 (2025).","journal-title":"ACS Nano"},{"key":"77547_CR33","doi-asserted-by":"publisher","first-page":"47762","DOI":"10.1021\/acsami.9b17598","volume":"11","author":"S Li","year":"2019","unstructured":"Li, S., Song, Z., Liu, C., Chen, X.-L. & Han, H. Biomimetic mineralization-based CRISPR\/Cas9 ribonucleoprotein nanoparticles for gene editing. ACS Appl. Mater. Interfaces 11, 47762\u201347770 (2019).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"77547_CR34","doi-asserted-by":"publisher","first-page":"38417","DOI":"10.1021\/acsami.9b12140","volume":"11","author":"Y Dong","year":"2019","unstructured":"Dong, Y. et al. pH-Sensitive shell\u2013core platform block DNA repair pathway to amplify irreversible DNA damage of triple negative breast cancer. ACS Applied Materials & Interfaces 11, 38417\u201338428 (2019).","journal-title":"ACS Applied Materials & Interfaces"},{"key":"77547_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42740-2","volume":"14","author":"J Yan","year":"2023","unstructured":"Yan, J. et al. An autocatalytic multicomponent DNAzyme nanomachine for tumor-specific photothermal therapy sensitization in pancreatic cancer. Nat. Commun. 14, 6905 (2023).","journal-title":"Nat. Commun."},{"key":"77547_CR36","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1002\/smll.201200217","volume":"8","author":"J Zhu","year":"2012","unstructured":"Zhu, J. et al. pH-Controlled delivery of doxorubicin to cancer cells, based on small mesoporous carbon nanospheres. Small 8, 2715\u20132720 (2012).","journal-title":"Small"},{"key":"77547_CR37","doi-asserted-by":"publisher","first-page":"9367845","DOI":"10.1155\/2019\/9367845","volume":"2019","author":"H Zuo","year":"2019","unstructured":"Zuo, H. iRGD: a promising peptide for cancer imaging and a potential therapeutic agent for various cancers. J. Oncol. 2019, 9367845 (2019).","journal-title":"J. Oncol."},{"key":"77547_CR38","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1023\/B:JOPC.0000020083.81718.55","volume":"23","author":"J Park","year":"2004","unstructured":"Park, J., Singh, B., Maj, M. C. & Gupta, R. S. Phosphorylated derivatives that activate or inhibit mammalian adenosine kinase provide insights into the role of pentavalent ions in AK catalysis. Protein J 23, 167\u2013177 (2004).","journal-title":"Protein J"},{"key":"77547_CR39","doi-asserted-by":"publisher","first-page":"2102271","DOI":"10.1002\/adma.202102271","volume":"33","author":"L Liang","year":"2021","unstructured":"Liang, L. et al. Calcium phosphate-reinforced metal-organic frameworks regulate adenosine-mediated immunosuppression. Adv. Mater. 33, 2102271 (2021).","journal-title":"Adv. Mater."},{"key":"77547_CR40","doi-asserted-by":"publisher","first-page":"eabh1261","DOI":"10.1126\/scitranslmed.abh1261","volume":"14","author":"C Mao","year":"2022","unstructured":"Mao, C. et al. Delivery of an ectonucleotidase inhibitor with ROS-responsive nanoparticles overcomes adenosine-mediated cancer immunosuppression. Sci. Transl. Med. 14, eabh1261 (2022).","journal-title":"Sci. Transl. Med."},{"key":"77547_CR41","doi-asserted-by":"publisher","first-page":"eadg3736","DOI":"10.1126\/sciadv.adg3736","volume":"9","author":"OS Sarkar","year":"2023","unstructured":"Sarkar, O. S. et al. Monocytic MDSCs exhibit superior immune suppression via adenosine, and depletion of adenosine improves the efficacy of immunotherapy. Sci. Adv. 9, eadg3736 (2023).","journal-title":"Sci. Adv."},{"key":"77547_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14060-x","volume":"11","author":"M Yu","year":"2020","unstructured":"Yu, M. et al. CD73 on cancer-associated fibroblasts enhanced by the A2B-mediated feedforward circuit enforces an immune checkpoint. Nat. Commun. 11, 515 (2020).","journal-title":"Nat. Commun."},{"key":"77547_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31044-6","volume":"13","author":"C Zhang","year":"2022","unstructured":"Zhang, C. et al. Catalytical nano-immunocomplexes for remote-controlled sono-metabolic checkpoint trimodal cancer therapy. Nat. Commun. 13, 3468 (2022).","journal-title":"Nat. Commun."},{"key":"77547_CR44","first-page":"2296","volume":"41","author":"S Lorenzen","year":"2018","unstructured":"Lorenzen, S. et al. Preliminary phase 1 profile of BMS-986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors. Oncol. Res. Treat. 41, 2296\u20135262 (2018).","journal-title":"Oncol. Res. Treat."},{"key":"77547_CR45","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1200\/JCO.2021.39.3_suppl.404","volume":"39","author":"GA Manji","year":"2021","unstructured":"Manji, G. A. et al. ARC-8: Phase I\/Ib study to evaluate safety and tolerability of AB680+ chemotherapy+ zimberelimab (AB122) in patients with treatment-naive metastatic pancreatic adenocarcinoma (mPDAC). J. Clin. Oncol. 39, 1527\u20137755 (2021).","journal-title":"J. Clin. Oncol."},{"key":"77547_CR46","doi-asserted-by":"publisher","first-page":"eaay3255","DOI":"10.1126\/sciadv.aay3255","volume":"5","author":"Y Rui","year":"2019","unstructured":"Rui, Y. et al. Carboxylated branched poly(\u03b2-amino ester) nanoparticles enable robust cytosolic protein delivery and CRISPR-Cas9 gene editing. Sci. Adv. 5, eaay3255 (2019).","journal-title":"Sci. Adv."},{"key":"77547_CR47","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/s41591-026-04244-6","volume":"32","author":"N An","year":"2026","unstructured":"An, N. et al. In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study. Nat. Med. 32, 1257\u20131266 (2026).","journal-title":"Nat. Med."},{"key":"77547_CR48","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1017\/erm.2025.10","volume":"27","author":"B Cetin","year":"2025","unstructured":"Cetin, B., Erendor, F., Eksi, Y. E., Sanlioglu, A. D. & Sanlioglu, S. Advancing CRISPR genome editing into gene therapy clinical trials: progress and future prospects. Expert Rev. Mol. Med. 27, e16 (2025).","journal-title":"Expert Rev. Mol. Med."},{"key":"77547_CR49","doi-asserted-by":"publisher","first-page":"102157","DOI":"10.1016\/j.cis.2020.102157","volume":"279","author":"R Khalifehzadeh","year":"2020","unstructured":"Khalifehzadeh, R. & Arami, H. Biodegradable calcium phosphate nanoparticles for cancer therapy. Adv. Colloid Interface Sci 279, 102157 (2020).","journal-title":"Adv. Colloid Interface Sci"},{"key":"77547_CR50","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1161\/ATVBAHA.118.311579","volume":"39","author":"P Joolharzadeh","year":"2019","unstructured":"Joolharzadeh, P. & St. Hilaire, C. CD73 (Cluster of Differentiation 73) and the differences between mice and humans. Arterioscler. Thromb. Vasc. Biol. 39, 339\u2013348 (2019).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"77547_CR51","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","volume":"15","author":"Q Cheng","year":"2020","unstructured":"Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing. Nat. Nanotechnol. 15, 313\u2013320 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"77547_CR52","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/nature16526","volume":"529","author":"BP Kleinstiver","year":"2016","unstructured":"Kleinstiver, B. P. et al. High-fidelity CRISPR\u2013Cas9 nucleases with no detectable genome-wide off-target effects. Nature 529, 490\u2013495 (2016).","journal-title":"Nature"},{"key":"77547_CR53","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.1247005","volume":"343","author":"O Shalem","year":"2014","unstructured":"Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84\u201387 (2014).","journal-title":"Science"},{"key":"77547_CR54","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","volume":"34","author":"JG Doench","year":"2016","unstructured":"Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat. Biotechnol. 34, 184\u2013191 (2016).","journal-title":"Nat. Biotechnol."},{"key":"77547_CR55","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.1231143","volume":"339","author":"L Cong","year":"2013","unstructured":"Cong, L. et al. Multiplex genome engineering using CRISPR\/Cas systems. Science 339, 819\u2013823 (2013).","journal-title":"Science"},{"key":"77547_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/srep07581","volume":"4","author":"X Chen","year":"2014","unstructured":"Chen, X. et al. Dual sgRNA-directed gene knockout using CRISPR\/Cas9 technology in Caenorhabditis elegans. Sci. Rep. 4, 7581 (2014).","journal-title":"Sci. Rep."},{"key":"77547_CR57","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/s41565-023-01378-3","volume":"18","author":"X Chen","year":"2023","unstructured":"Chen, X. et al. Non-invasive activation of intratumoural gene editing for improved adoptive T-cell therapy in solid tumors. Nat. Nanotechnol. 18, 933\u2013944 (2023).","journal-title":"Nat. Nanotechnol."},{"key":"77547_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17029-3","volume":"11","author":"T Wei","year":"2020","unstructured":"Wei, T., Cheng, Q., Min, Y.-L., Olson, E. N. & Siegwart, D. J. Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue-specific genome editing. Nat. Commun. 11, 3232 (2020).","journal-title":"Nat. Commun."},{"key":"77547_CR59","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ccell.2016.06.025","volume":"30","author":"A Young","year":"2016","unstructured":"Young, A. et al. Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses. Cancer Cell 30, 391\u2013403 (2016).","journal-title":"Cancer Cell"},{"key":"77547_CR60","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1158\/2159-8290.CD-19-0541","volume":"9","author":"X-Y Li","year":"2019","unstructured":"Li, X.-Y. et al. Targeting CD39 in cancer reveals an extracellular ATP-and inflammasome-driven tumor immunity. Cancer Discov 9, 1754\u20131773 (2019).","journal-title":"Cancer Discov"},{"key":"77547_CR61","doi-asserted-by":"publisher","first-page":"5626","DOI":"10.1158\/1078-0432.CCR-13-0545","volume":"19","author":"B Allard","year":"2013","unstructured":"Allard, B., Pommey, S., Smyth, M. J. & Stagg, J. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin. Cancer Res. 19, 5626\u20135635 (2013).","journal-title":"Clin. Cancer Res."},{"key":"77547_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22407-6","volume":"12","author":"J Liu","year":"2021","unstructured":"Liu, J. et al. Co-delivery of IOX1 and doxorubicin for antibody-independent cancer chemo-immunotherapy. Nat. Commun. 12, 2425 (2021).","journal-title":"Nat. Commun."},{"key":"77547_CR63","doi-asserted-by":"publisher","first-page":"e202313968","DOI":"10.1002\/anie.202313968","volume":"62","author":"S Feng","year":"2023","unstructured":"Feng, S. et al. A gene-editable palladium-based bioorthogonal nanoplatform facilitates macrophage phagocytosis for tumor therapy. Angew. Chem. Int. Ed. 62, e202313968 (2023).","journal-title":"Angew. Chem. Int. Ed."},{"key":"77547_CR64","doi-asserted-by":"publisher","first-page":"eaaw8922","DOI":"10.1126\/sciadv.aaw8922","volume":"5","author":"C Liu","year":"2019","unstructured":"Liu, C. et al. A boronic acid\u2013rich dendrimer with robust and unprecedented efficiency for cytosolic protein delivery and CRISPR-Cas9 gene editing. Sci. Adv. 5, eaaw8922 (2019).","journal-title":"Sci. Adv."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77547-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77547-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77547-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:41:37Z","timestamp":1791499297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77547-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["77547"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-77547-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"17 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"10628"}}